ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
| Revenue (TTM) | $509.86M |
| Gross Profit (TTM) | $312.42M |
| EBITDA | $214.82M |
| Operating Margin | -123.40% |
| Return on Equity | 43.30% |
| Return on Assets | 22.00% |
| Revenue/Share (TTM) | $2.14 |
| Book Value | $1.68 |
| Price-to-Book | 5.02 |
| Price-to-Sales (TTM) | 3.75 |
| EV/Revenue | 3.971 |
| EV/EBITDA | 9.14 |
| Quarterly Earnings Growth (YoY) | -52.80% |
| Quarterly Revenue Growth (YoY) | 15.90% |
| Shares Outstanding | $231.77M |
| Float | $226.73M |
| % Insiders | 1.86% |
| % Institutions | 93.89% |
Volatility is currently contracting